Realcan Pharmaceutical Group Co., Ltd. (SHE:002589)
China
· Delayed Price · Currency is CNY 3.250
+0.030 (0.93%)
Apr 29, 2026, 3:04 PM CST
SHE:002589 Revenue
Realcan Pharmaceutical Group had revenue of 1.71B CNY in the quarter ending March 31, 2026, a decrease of -2.80%. This brings the company's revenue in the last twelve months to 7.25B, down -5.94% year-over-year. In the year 2025, Realcan Pharmaceutical Group had annual revenue of 7.30B, down -8.42%.
Revenue (ttm)
7.25B
Revenue Growth
-5.94%
P/S Ratio
0.66
Revenue / Employee
2.50M
Employees
2,897
Market Cap
4.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.30B | -670.49M | -8.42% |
| Dec 31, 2024 | 7.97B | -68.02M | -0.85% |
| Dec 31, 2023 | 8.03B | -4.28B | -34.74% |
| Jan 1, 2023 | 12.31B | -8.75B | -41.54% |
| Jan 1, 2022 | 21.06B | -6.17B | -22.67% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Guangxi LiuYao Group | 20.95B |
| Shenzhen Glory Medical | 1.20B |
| C.Q. Pharmaceutical Holding | 82.27B |
| China National Accord Medicines Corporation | 72.95B |
| Qingdao Baheal Medical INC. | 7.58B |
| China Meheco Group | 35.36B |
| Liaoning Cheng Da | 9.90B |
| China National Medicines Corporation | 53.31B |